Tumor Biology

, Volume 35, Issue 4, pp 3421–3430 | Cite as

Tetra-arsenic tetra-sulfide (As4S4) promotes apoptosis in retinoid acid -resistant human acute promyelocytic leukemic NB4-R1 cells through downregulation of SET protein

  • Yanfeng Liu
  • Pengcheng He
  • Feng Liu
  • Naicen Zhou
  • Xiaoyan Cheng
  • Lili Shi
  • Huachao Zhu
  • Jing Zhao
  • Yuan Wang
  • Mei Zhang
Research Article

Abstract

Tetra-arsenic tetra-sulfide (As4S4) is an arsenic compound with antitumor activity, especially in acute promyelocytic leukemia (APL) that are resistant to retinoic acid (RA). Although recent studies have revealed that the therapeutic action of As4S4 is closely associated with the induction of cellular apoptosis, the exact molecular mechanism underlying this action in RA-resistant APL remains to be clarified. In this study, we found that As4S4-induced apoptosis was accompanied by reduced mRNA and protein expression of SET gene in RA-resistant NB4-R1 cells. Moreover, RNAi knockdown of SET gene further promoted As4S4-induced apoptosis, while SET overexpression recovered the cell viability, suggesting that As4S4 induces apoptosis through the reduction of SET protein in NB4-R1 cells. We also observed that the knockdown of SET gene resulted in the upregulation of protein phosphatase 2 (PP2A) expression and the downregulation of promyelocytic leukemia and retinoic acid receptor α fusion gene (PML-RARα) expression, which were enhanced by As4S4 treatments. By contrast, overexpression of SET gene resulted in PP2A downregulation and PML-RARα upregulation, which were abolished by As4S4 pretreatment. Since PP2A is a proapoptotic factor and PML-RARα is an antiapoptotic factor, our results suggest that As4S4-induced apoptosis in RA-resistant NB4-R1 cells is through the downregulation of SET protein expression, which, in turn, increases PP2A and reduces PML-RARα expressions to lead to cell apoptosis.

Keywords

Tetra-arsenic tetra-sulfide (As4S4Acute promyelocytic leukemia SET/TAF-1 β PML-RARα Retinoic acid (RA) Protein phosphatase 2 (PP2A) Apoptosis 

Notes

Acknowledgments

This study was supported by the Natural Science Foundation of China (81000218), the Fundamental Research Funds for the Central Universities, the Shaanxi Province Science, and Technology Development Fund, China (nos. 2010 K01-135 and 2012KTCL03-12). The authors express their gratitude to Dr. Xinyang Wang and Dr. Wen Wen for their technological assistance.

Conflicts of interest

None.

References

  1. 1.
    Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood. 2008;111:2505–15.PubMedCrossRefGoogle Scholar
  2. 2.
    Falanga A, Rickles FR. Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemia. Best Pract Res Clin Haematol. 2003;16:463–82.PubMedCrossRefGoogle Scholar
  3. 3.
    Mattson JC. Acute promyelocytic leukemia. From morphology to molecular lesions. Clin Lab Med. 2000;20:83–103. ix.PubMedGoogle Scholar
  4. 4.
    Martens JH, Brinkman AB, Simmer F, Francoijs KJ, Nebbioso A, Ferrara F, et al. PML-RARalpha/RXR alters the epigenetic landscape in acute promyelocytic leukemia. Cancer Cell. 2010;17:173–85.PubMedCrossRefGoogle Scholar
  5. 5.
    Kamimura T, Miyamoto T, Harada M, Akashi K. Advances in therapies for acute promyelocytic leukemia. Cancer Sci. 2011;102:1929–37.PubMedCrossRefGoogle Scholar
  6. 6.
    Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, et al. Gruppo Italiano Malattie Ematologiche dell'Adulto; German-Austrian Acute Myeloid Leukemia Study Group; Study Alliance Leukemia. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369:111–21.PubMedCrossRefGoogle Scholar
  7. 7.
    Degos L, Wang ZY. All trans retinoic acid in acute promyelocytic leukemia. Oncogene. 2001;20:7140–5.PubMedCrossRefGoogle Scholar
  8. 8.
    Breccia M, Lo-Coco F. Arsenic trioxide for management of acute promyelocytic leukemia: current evidence on its role in front-line therapy and recurrent disease. Expert Opin Pharmacother. 2012;13:1031–43.PubMedCrossRefGoogle Scholar
  9. 9.
    Cunningham I, Gee TS, Reich LM, Kempin SJ, Naval AN, Clarkson BD. Acute promyelocytic leukemia: treatment results during a decade at Memorial Hospital. Blood. 1989;73:1116–22.PubMedGoogle Scholar
  10. 10.
    Hoffman E, Mielicki WP. All-trans retinoic acid (ATRA) in prevention and cancer therapy. Postepy Hig Med Dosw (Online). 2010;64:284–90.Google Scholar
  11. 11.
    Ravandi F, Estey E, Jones D, Faderl S, O'Brien S, Fiorentino J, et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol. 2009;27:504–10.PubMedCrossRefGoogle Scholar
  12. 12.
    Holmes D, Vishnu P, Dorer RK, Aboulafia DM. All-trans retinoic acid-induced pseudotumor cerebri during induction therapy for acute promyelocytic leukemia: a case report and literature review. Case Rep Oncol Med. 2012;2012:313057.PubMedCentralPubMedGoogle Scholar
  13. 13.
    Zayed A, Couban S, Hayne O, Sparavalo N, Shawwa A, Sadek I, et al. Acute promyelocytic leukemia: a novel PML/RARalpha fusion that generates a frameshift in the RARalpha transcript and ATRA resistance. Leuk Lymphoma. 2007;48:489–96.PubMedCrossRefGoogle Scholar
  14. 14.
    Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ, Si GY, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood. 1996;88:1052–61.PubMedGoogle Scholar
  15. 15.
    Mathews V, George B, Lakshmi KM, Viswabandya A, Bajel A, Balasubramanian P, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood. 2006;107:2627–32.PubMedCrossRefGoogle Scholar
  16. 16.
    Mathews V, Chendamarai E, George B, Viswabandya A, Srivastava A. Treatment of acute promyelocytic leukemia with single-agent arsenic trioxide. Mediterr J Hematol Infect Dis. 2011;3:e2011056.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Wang FR, Lou YQ, Lu DP. A clinical pharmacokinetic study of multi-dose oral tetra-arsenic tetra-sulfide combination therapy in acute promyelocytic leukemia. Zhonghua Nei Ke Za Zhi. 2005;44:730–3.PubMedGoogle Scholar
  18. 18.
    Lu DP, Qiu JY, Jiang B, Wang Q, Liu KY, Liu YR, et al. Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report. Blood. 2002;99:3136–43.PubMedCrossRefGoogle Scholar
  19. 19.
    Yin T, Wu YL, Sun HP, Sun GL, Du YZ, Wang KK, et al. Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein. Blood. 2004;104:4219–25.PubMedCrossRefGoogle Scholar
  20. 20.
    Teng ZP, Zhang P, Zhu HH, Hao HY, Qin XY, Hao L, et al. Mechanism of tetra-arsenic tetra-sulfide in inducing apoptosis of acute promyelocytic leukemia cells. Beijing Da Xue Xue Bao. 2006;38:236–8.PubMedGoogle Scholar
  21. 21.
    Wang JZ, Liu YR, Qin YZ, Jiang H, Wang FR, Bao L, et al. Change of PML/PML-RARalpha protein during treatment with tetraarsenic tetrasulfide (As4S4) in patients with acute promyelocytic leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2003;11:464–8.PubMedGoogle Scholar
  22. 22.
    Qi J, He P, Chen W, Wang H, Wang X, Zhang M. Comparative proteome study of apoptosis induced by As4S4 in retinoid acid resistant human acute promyelocytic leukemia NB4-R1 cells. Leuk Res. 2010;34:1506–16.PubMedCrossRefGoogle Scholar
  23. 23.
    Kogan SC. Curing APL: differentiation or destruction? Cancer Cell. 2009;15:7–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Tallman MS. What is the role of arsenic in newly diagnosed APL? Best Pract Res Clin Haematol. 2008;21:659–66.PubMedCrossRefGoogle Scholar
  25. 25.
    Balaz P, Sedlak J. Arsenic in cancer treatment: challenges for application of realgar nanoparticles (a minireview). Toxins (Basel). 2010;2:1568–81.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Ye HQ, Gan L, Yang XL, Xu HB. Membrane toxicity accounts for apoptosis induced by realgar nanoparticles in promyelocytic leukemia HL-60 cells. Biol Trace Elem Res. 2005;103:117–32.PubMedCrossRefGoogle Scholar
  27. 27.
    Wang XB, Gao HY, Hou BL, Huang J, Xi RG, Wu LJ. Nanoparticle realgar powders induce apoptosis in U937 cells through caspase MAPK and mitochondrial pathways. Arch Pharm Res. 2007;30:653–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Tse WP, Cheng CH, Che CT, Zhao M, Fan RQ, Lin ZX. Realgar-mediated growth inhibition on HaCaT human keratinocytes is associated with induction of apoptosis. Int J Mol Med. 2009;24:189–96.PubMedGoogle Scholar
  29. 29.
    Cervoni N, Detich N, Seo SB, Chakravarti D, Szyf M. The oncoprotein Set/TAF-1beta, an inhibitor of histone acetyltransferase, inhibits active demethylation of DNA, integrating DNA methylation and transcriptional silencing. J Biol Chem. 2002;277:25026–31.PubMedCrossRefGoogle Scholar
  30. 30.
    Santa-Coloma TA. Anp32e (Cpd1) and related protein phosphatase 2 inhibitors. Cerebellum. 2003;2:310–20.PubMedCrossRefGoogle Scholar
  31. 31.
    Li M, Makkinje A, Damuni Z. The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A. J Biol Chem. 1996;271:11059–62.PubMedCrossRefGoogle Scholar
  32. 32.
    Adler HT, Nallaseth FS, Walter G, Tkachuk DC. HRX leukemic fusion proteins form a heterocomplex with the leukemia-associated protein SET and protein phosphatase 2A. J Biol Chem. 1997;272:28407–14.PubMedCrossRefGoogle Scholar
  33. 33.
    Ouellet V, Le Page C, Guyot MC, Lussier C, Tonin PN, Provencher DM, et al. SET complex in serous epithelial ovarian cancer. Int J Cancer. 2006;119:2119–26.PubMedCrossRefGoogle Scholar
  34. 34.
    Carlson SG, Eng E, Kim EG, Perlman EJ, Copeland TD, Ballermann BJ. Expression of SET, an inhibitor of protein phosphatase 2A, in renal development and Wilms' tumor. J Am Soc Nephrol. 1998;9:1873–80.PubMedGoogle Scholar
  35. 35.
    Fornerod M, Boer J, van Baal S, Jaeglé M, von Lindern M, Murti KG, et al. Relocation of the carboxyterminal part of CAN from the nuclear envelope to the nucleus as a result of leukemia-specific chromosome rearrangements. Oncogene. 1995;10:1739–48.PubMedGoogle Scholar
  36. 36.
    Cristobal I, Garcia-Orti L, Cirauqui C, Cortes-Lavaud X, García-Sánchez MA, Calasanz MJ, et al. Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia. Haematologica. 2012;97:543–50.PubMedCentralPubMedCrossRefGoogle Scholar
  37. 37.
    Janssens V, Goris J. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J. 2001;353:417–39.PubMedCentralPubMedCrossRefGoogle Scholar
  38. 38.
    Janssens V, Rebollo A. The role and therapeutic potential of Ser/Thr phosphatase PP2A in apoptotic signalling networks in human cancer cells. Curr Mol Med. 2012;12:268–87.PubMedCrossRefGoogle Scholar
  39. 39.
    Perrotti D, Neviani P. Protein phosphatase 2A: a target for anticancer therapy. Lancet Oncol. 2013;14:e229–38.PubMedCentralPubMedCrossRefGoogle Scholar
  40. 40.
    Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Liu S, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell. 2005;8:355–68.PubMedCrossRefGoogle Scholar
  41. 41.
    Lin QDWX, Wang P, Liu YY, Zhang LN, Li YF. Application of all-trans retinoic acid combining chemotherapy and As4S4 in the maintenance treatment of patients with acute promyelocytic leukemia. Zhonghua Xue Ye Xue Za Zhi. 2007;28:19–21.PubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Yanfeng Liu
    • 1
  • Pengcheng He
    • 1
  • Feng Liu
    • 1
  • Naicen Zhou
    • 1
  • Xiaoyan Cheng
    • 1
  • Lili Shi
    • 1
  • Huachao Zhu
    • 1
  • Jing Zhao
    • 1
  • Yuan Wang
    • 1
  • Mei Zhang
    • 1
  1. 1.Department of Hematology, The First Affiliated Hospital, School of MedicineXi’an Jiaotong UniversityXi’anChina

Personalised recommendations